Erlotinib in the DBM context

Print
Published on Sunday, 27 January 2013

Using minimum doses of Erlotinib in the DBM contextUsing minimum doses of Erlotinib in the DBM context

 

In rare critical situations (but not in fixed part DBM) in an advanced multi-metastatic stage even in other not-epithelial breast forms, as metastatic parotid cancer [our recent publication about cervicofacial cancer (NeuroEndocrinology Letters 2012 May 14; 33(3): 249-256.)], minimum quantities of Erlotinib (25 mg, instead of 150 mg usually prescribed in oncology) have had some positive effects in the multi therapeutic context DBM (The Di Bella Method).

Recent research on crossed interactivity among ER, EGFR, IGF1R, GHR, and GHRHR supports the rational use of the molecule in these situations: the selective inhibition of the signaling pathways proliferative tyrosine kinase adds itself in a synergistic way at the downstream inactivation of the same cascade (cAMP - dependent protein kinase and MAPK ) induced by SST (activation of phosphatase and relative dephosphorylation) and prolactin inhibitors.

The dose is tolerated and in the differentiating therapeutic context, antitoxic, protective-epithelium and physiological growth activator, as a Solution of Retinoids, Vitamin D3, Melatonin (MLT), has given some positive effect in almost total absence of toxicity, outside of protocol schematisms with which the use had been formulated.

The Di Bella Method (DBM) is absolutely antithetical to the stereotyped, registered, encoded and formal mentality of oncology paradigms, but it is using a product without prejudice or preconceptions in a physiological biochemical context when there are reasoned and justified information, especially if regularly confirmed, as in these cases, by clinical response!

M.D. - PhD Giuseppe Di Bella

Transcripted by: P.Cinzia Pierucci